Search clinical trials for: CKD-344

Total 1960 results

City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Stage IV Prostate Adenocarcinoma AJCC v7 | PSA Level Greater Than Two

United States
University of Arkansas

Active, not recruiting

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Multiple Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Plasma Cell Myeloma | RISS Stage I Plasma Cell Myeloma | RISS Stage II Plasma Cell Myeloma

United States
University of Arkansas

Active, not recruiting

Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

Myeloma

United States
BRC Operations Pty. Ltd.

Unknown

International Study to Predict Optimised Treatment in Attention Deficit/Hyperactivity Disorder

Attention Deficit/Hyperactivity Disorder

United States, Australia, Netherlands
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

Moderate to Severe Glabellar Frown Lines

United States, Canada
Medical College of Wisconsin

Completed

Topical Antisepsis in Head and Neck Cancer Surgery

Head and Neck Cancer

United States
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Moderate to Severe Glabellar Frown Lines

United States
National Cancer Institute (NCI)

Completed

Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer

United States, Canada
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Terminated

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Merck KGaA, Darmstadt, Germany
Merck Serono S.P.A., Italy

Completed

Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a (CONTAIN)

Multiple Sclerosis

Italy
WiSP Wissenschaftlicher Service Pharma GmbH

Completed

Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy (DSMM-II)

Multiple Myeloma
Cytokinetics

Recruiting

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM (MAPLE-HCM)

Obstructive Hypertrophic Cardiomyopathy (oHCM)

United States, Denmark, Spain, Netherlands, United Kingdom, France, China, Israel, Germany, Italy, Hungary, Canada
Laboratorios Andromaco S.A.

Completed

Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product

Therapeutic Equivalency

India
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); Sanofi

Recruiting

Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

AL Amyloidosis

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Completed

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Plasma Cell Leukemia

United States
Emory University
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Recruiting

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Renal Failure | Plasma Cell Myeloma

United States
Stefan Soderberg
University of Edinburgh

Completed

Leptin Infusion and Endothelial Vasomotor Response (LIVARM)

Obesity | Endothelial Dysfunction | Vasodilation | Venous Occlusion Plethysmography

Sweden, United Kingdom
University of Calgary

Completed

The Effect of Citrasate Dialysate on Heparin Dose in Hemodialysis

Chronic Kidney Disease

Canada
Hoffmann-La Roche

Recruiting

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of, France, Spain, Taiwan, United States, Israel, Australia, United Kingdom
National Cancer Institute (NCI)

Completed

Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer (TARGET)

Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
VA Office of Research and Development
University of California, San Francisco

Recruiting

Novel Combination Therapy for Osteoporosis in Men (Osteo-Men)

Male Osteoporosis

United States
University of Virginia

Recruiting

FDG and FDOPA PET Demonstration of Functional Brain Abnormalities

Glioblastoma

United States
University of California, San Francisco
National Cancer Institute (NCI)

Terminated

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

Prostate Adenocarcinoma

United States
University of Arkansas

Active, not recruiting

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Multiple Myeloma

United States
Aristotle University Of Thessaloniki

Completed

Efficacy and Safety of Mydriatic Microdrops Compared With Standard Drops for Retinopathy of Prematurity (ROP) Screening: a Pilot Randomized Clinical Trial

Retinopathy of Prematurity

Greece
LI YAN

Completed

Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics

Kidney Transplant Patients

China
Jonsson Comprehensive Cancer Center
Janssen Inc.

Active, not recruiting

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Recurrent Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation

United States
Ohio State University Comprehensive Cancer Center
ImmunoGen, Inc.; Clovis Oncology, Inc.

Active, not recruiting

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Folate Receptor Alpha Positive | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Recurrent Uterine Serous Carcinoma | Recurrent Uterine Carcinosarcoma | Platinum...

United States
Jennifer Lee Caswell-Jin
National Cancer Institute (NCI); QED Therapeutics, Inc.

Terminated

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer

United States
Grifols Therapeutics LLC

Completed

Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)

Alpha 1-Antitrypsin Deficiency

Denmark, Sweden, United Kingdom
Monica Levy Andersen

Completed

Mother-caregivers of Children With Duchenne Muscular Dystrophy (DMDK)

Other Diseases or Conditions

Brazil
Laboratorios Andromaco S.A.

Completed

Bioavailability of Levonorgestrel and Ethinyl Estradiol Tablets 15.0 mg/0.03 mg With Regards to Reference Product

Bioequivalence

Chile
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Plasmablastic Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell... and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Brigham and Women's Hospital; Weill Medical College of Cornell University; The... and other collaborators

Completed

Cognitive Changes Associated With Breast Cancer Treatment

Breast Cancer | Cognitive Side Effects of Cancer Treatments | Stage I, II and III A Breast Cancer

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
VA Office of Research and Development

Recruiting

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT)

Recurrent Prostate Cancer | Prostate Cancer | Metastatic Prostate Cancer | Oligometastasis | Oligorecurrence | De Novo Prostate Cancer

United States
St. Jude Children's Research Hospital
Pfizer

Recruiting

Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Prostate Carcinoma

United States
University of Iowa
National Cancer Institute (NCI)

Terminated

Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

Multiple Myeloma

United States
M.D. Anderson Cancer Center

Recruiting

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin Lymphoma

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma

Glioblastoma | Gliosarcoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

Prostate Adenocarcinoma | Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma

Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma

United States

Search clinical trials for: CKD-344

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations